Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores

An inverse correlation between Kt/V and epoetin requirement has recently been demonstrated in stable hemodialysis (HD) patients with adequate iron stores, dialyzed with cellulosic membranes. However, there is no evidence as to whether or not this effect continues for Kt/V even in the adequate or hig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of nephrology 2003-07, Vol.16 (4), p.546-551
Hauptverfasser: Movilli, Ezio, Cancarini, Giovanni C, Vizzardi, Valerio, Camerini, Corrado, Brunori, Giuliano, Cassamali, Silvia, Maiorca, Rosario
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 551
container_issue 4
container_start_page 546
container_title Journal of nephrology
container_volume 16
creator Movilli, Ezio
Cancarini, Giovanni C
Vizzardi, Valerio
Camerini, Corrado
Brunori, Giuliano
Cassamali, Silvia
Maiorca, Rosario
description An inverse correlation between Kt/V and epoetin requirement has recently been demonstrated in stable hemodialysis (HD) patients with adequate iron stores, dialyzed with cellulosic membranes. However, there is no evidence as to whether or not this effect continues for Kt/V even in the adequate or higher range. We investigated the relationship between Kt/V and the weekly epoetin dose in 85 stable HD patients (age 63 +/- 16 years) treated with bicarbonate HD and unsubstituted cellulose membranes for 6-338 months (median: 70 months). HD for at least 6 months, subcutaneous rHuEPO for at least 4 months, transferrin saturation (TSAT) > or = 20%, serum ferritin > or = 100 ng/mL, hemoglobin (Hb) level targeted to approximately equal to 12 g/dL for at least 3 months. HBsAg and HIV positivity; need for blood transfusions or evidence of blood loss in the 3 months before the study, acute and chronic infections. To evaluate the effect of dialysis adequacy on the epoetin requirement, we also performed the same analysis after dividing of the patients according to Kt/V. Hematocrit (Hct) and Hb levels were evaluated weekly for 3 weeks; TSAT, serum ferritin, Kt/V, PCRn, serum albumin (sAlb), and weekly epoetin dose were evaluated at the end of observation. No change in dialysis or therapy prescription was made during the study. The results for all the patients were: Hct 36 +/- 2 %, Hb 12 +/- 0.7 g/dL, TSAT 28 +/- 7%, serum ferritin 234 +/- 171 ng/mL, sAlb 4.2 +/- 0.4 g/dL, Kt/V 1.33 +/- 0.17, PCRn 1.15 +/- 0.28 g/Kg/day, weekly epoetin dose 117 +/- 74 U/Kg. There was no correlation between Hb and Kt/V, whereas there was an inverse correlation between the reciprocal of the weekly epoetin dose and Kt/V (r = -0.448, p = 0.0001). Further regression line analysis showed a break-point for Kt/V at the level of 1.33. In the 52 patients with Kt/V < 1.33, the correlation was confirmed between epoetin and Kt/V (r = - 0.563, p = 0.0001), while in the 33 patients with Kt/V > or = 1.33, there was no correlation between epoetin dose and Kt/V (r = 0.021, p = NS). In these patients, multiple regression analysis, with the weekly epoetin dose as a dependent variable, confirmed Kt/V as a non-significant factor. In iron-replete HD patients on cellulosic membranes and stabilized epoetin therapy, inadequate dialysis was associated with higher epoetin requirement, but for Kt/V values > or = 1.33, there was no further effect on epoetin responsiveness.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71496651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71496651</sourcerecordid><originalsourceid>FETCH-LOGICAL-p547-f9ced04d0f607fd7025e7f98230919683d7a6923356bb49725b0d0a1a0f107da3</originalsourceid><addsrcrecordid>eNpFkEFOwzAQRbMA0VK4AvKKXcCOHTveIKGqFEQFm-4jp55Qo8RObUdVr8NJcaGI1Yw0f97_M2fZlJCC5BUrqkl2GcInxkVZFuwimxDGJRelmGZfi8FBNBZ52I3GQw82Iu0gIOtSAwNYjZxF2qjuEExIswBovwWLXuP9G3pA5I5SlACDiiYth6Paw8fYKf-_FT2o-MPem7hFG-i6sXPBbFAPfeOVTYYqOSmdYqgIyPiECdF5CFfZeau6ANenOsvWT4v1_DlfvS9f5o-rfCiZyFu5AY2Zxi3HotUi3QqilVVBsSSSV1QLxWVBacmbhklRlA3WWBGFW4KFVnSW3f5iB-92I4RY9yYcg6Zwbgy1IExyXpIkvDkJx6YHXQ_e9Mof6r-n0m9I9HR7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71496651</pqid></control><display><type>article</type><title>Epoetin requirement does not depend on dialysis dose when Kt/N &gt; 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Movilli, Ezio ; Cancarini, Giovanni C ; Vizzardi, Valerio ; Camerini, Corrado ; Brunori, Giuliano ; Cassamali, Silvia ; Maiorca, Rosario</creator><creatorcontrib>Movilli, Ezio ; Cancarini, Giovanni C ; Vizzardi, Valerio ; Camerini, Corrado ; Brunori, Giuliano ; Cassamali, Silvia ; Maiorca, Rosario</creatorcontrib><description>An inverse correlation between Kt/V and epoetin requirement has recently been demonstrated in stable hemodialysis (HD) patients with adequate iron stores, dialyzed with cellulosic membranes. However, there is no evidence as to whether or not this effect continues for Kt/V even in the adequate or higher range. We investigated the relationship between Kt/V and the weekly epoetin dose in 85 stable HD patients (age 63 +/- 16 years) treated with bicarbonate HD and unsubstituted cellulose membranes for 6-338 months (median: 70 months). HD for at least 6 months, subcutaneous rHuEPO for at least 4 months, transferrin saturation (TSAT) &gt; or = 20%, serum ferritin &gt; or = 100 ng/mL, hemoglobin (Hb) level targeted to approximately equal to 12 g/dL for at least 3 months. HBsAg and HIV positivity; need for blood transfusions or evidence of blood loss in the 3 months before the study, acute and chronic infections. To evaluate the effect of dialysis adequacy on the epoetin requirement, we also performed the same analysis after dividing of the patients according to Kt/V. Hematocrit (Hct) and Hb levels were evaluated weekly for 3 weeks; TSAT, serum ferritin, Kt/V, PCRn, serum albumin (sAlb), and weekly epoetin dose were evaluated at the end of observation. No change in dialysis or therapy prescription was made during the study. The results for all the patients were: Hct 36 +/- 2 %, Hb 12 +/- 0.7 g/dL, TSAT 28 +/- 7%, serum ferritin 234 +/- 171 ng/mL, sAlb 4.2 +/- 0.4 g/dL, Kt/V 1.33 +/- 0.17, PCRn 1.15 +/- 0.28 g/Kg/day, weekly epoetin dose 117 +/- 74 U/Kg. There was no correlation between Hb and Kt/V, whereas there was an inverse correlation between the reciprocal of the weekly epoetin dose and Kt/V (r = -0.448, p = 0.0001). Further regression line analysis showed a break-point for Kt/V at the level of 1.33. In the 52 patients with Kt/V &lt; 1.33, the correlation was confirmed between epoetin and Kt/V (r = - 0.563, p = 0.0001), while in the 33 patients with Kt/V &gt; or = 1.33, there was no correlation between epoetin dose and Kt/V (r = 0.021, p = NS). In these patients, multiple regression analysis, with the weekly epoetin dose as a dependent variable, confirmed Kt/V as a non-significant factor. In iron-replete HD patients on cellulosic membranes and stabilized epoetin therapy, inadequate dialysis was associated with higher epoetin requirement, but for Kt/V values &gt; or = 1.33, there was no further effect on epoetin responsiveness.</description><identifier>ISSN: 1121-8428</identifier><identifier>PMID: 14696757</identifier><language>eng</language><publisher>Italy</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biocompatible Materials ; Cellulose ; Cohort Studies ; Dialysis Solutions - pharmacology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Erythropoietin - administration &amp; dosage ; Female ; Follow-Up Studies ; Humans ; Iron - blood ; Iron - metabolism ; Kidney Failure, Chronic - diagnosis ; Kidney Failure, Chronic - therapy ; Kidney Function Tests ; Male ; Membranes, Artificial ; Middle Aged ; Multivariate Analysis ; Probability ; Recombinant Proteins ; Regression Analysis ; Renal Dialysis - instrumentation ; Renal Dialysis - methods ; Risk Assessment ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Journal of nephrology, 2003-07, Vol.16 (4), p.546-551</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14696757$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Movilli, Ezio</creatorcontrib><creatorcontrib>Cancarini, Giovanni C</creatorcontrib><creatorcontrib>Vizzardi, Valerio</creatorcontrib><creatorcontrib>Camerini, Corrado</creatorcontrib><creatorcontrib>Brunori, Giuliano</creatorcontrib><creatorcontrib>Cassamali, Silvia</creatorcontrib><creatorcontrib>Maiorca, Rosario</creatorcontrib><title>Epoetin requirement does not depend on dialysis dose when Kt/N &gt; 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores</title><title>Journal of nephrology</title><addtitle>J Nephrol</addtitle><description>An inverse correlation between Kt/V and epoetin requirement has recently been demonstrated in stable hemodialysis (HD) patients with adequate iron stores, dialyzed with cellulosic membranes. However, there is no evidence as to whether or not this effect continues for Kt/V even in the adequate or higher range. We investigated the relationship between Kt/V and the weekly epoetin dose in 85 stable HD patients (age 63 +/- 16 years) treated with bicarbonate HD and unsubstituted cellulose membranes for 6-338 months (median: 70 months). HD for at least 6 months, subcutaneous rHuEPO for at least 4 months, transferrin saturation (TSAT) &gt; or = 20%, serum ferritin &gt; or = 100 ng/mL, hemoglobin (Hb) level targeted to approximately equal to 12 g/dL for at least 3 months. HBsAg and HIV positivity; need for blood transfusions or evidence of blood loss in the 3 months before the study, acute and chronic infections. To evaluate the effect of dialysis adequacy on the epoetin requirement, we also performed the same analysis after dividing of the patients according to Kt/V. Hematocrit (Hct) and Hb levels were evaluated weekly for 3 weeks; TSAT, serum ferritin, Kt/V, PCRn, serum albumin (sAlb), and weekly epoetin dose were evaluated at the end of observation. No change in dialysis or therapy prescription was made during the study. The results for all the patients were: Hct 36 +/- 2 %, Hb 12 +/- 0.7 g/dL, TSAT 28 +/- 7%, serum ferritin 234 +/- 171 ng/mL, sAlb 4.2 +/- 0.4 g/dL, Kt/V 1.33 +/- 0.17, PCRn 1.15 +/- 0.28 g/Kg/day, weekly epoetin dose 117 +/- 74 U/Kg. There was no correlation between Hb and Kt/V, whereas there was an inverse correlation between the reciprocal of the weekly epoetin dose and Kt/V (r = -0.448, p = 0.0001). Further regression line analysis showed a break-point for Kt/V at the level of 1.33. In the 52 patients with Kt/V &lt; 1.33, the correlation was confirmed between epoetin and Kt/V (r = - 0.563, p = 0.0001), while in the 33 patients with Kt/V &gt; or = 1.33, there was no correlation between epoetin dose and Kt/V (r = 0.021, p = NS). In these patients, multiple regression analysis, with the weekly epoetin dose as a dependent variable, confirmed Kt/V as a non-significant factor. In iron-replete HD patients on cellulosic membranes and stabilized epoetin therapy, inadequate dialysis was associated with higher epoetin requirement, but for Kt/V values &gt; or = 1.33, there was no further effect on epoetin responsiveness.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biocompatible Materials</subject><subject>Cellulose</subject><subject>Cohort Studies</subject><subject>Dialysis Solutions - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Erythropoietin - administration &amp; dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Iron - blood</subject><subject>Iron - metabolism</subject><subject>Kidney Failure, Chronic - diagnosis</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Kidney Function Tests</subject><subject>Male</subject><subject>Membranes, Artificial</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Probability</subject><subject>Recombinant Proteins</subject><subject>Regression Analysis</subject><subject>Renal Dialysis - instrumentation</subject><subject>Renal Dialysis - methods</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>1121-8428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFOwzAQRbMA0VK4AvKKXcCOHTveIKGqFEQFm-4jp55Qo8RObUdVr8NJcaGI1Yw0f97_M2fZlJCC5BUrqkl2GcInxkVZFuwimxDGJRelmGZfi8FBNBZ52I3GQw82Iu0gIOtSAwNYjZxF2qjuEExIswBovwWLXuP9G3pA5I5SlACDiiYth6Paw8fYKf-_FT2o-MPem7hFG-i6sXPBbFAPfeOVTYYqOSmdYqgIyPiECdF5CFfZeau6ANenOsvWT4v1_DlfvS9f5o-rfCiZyFu5AY2Zxi3HotUi3QqilVVBsSSSV1QLxWVBacmbhklRlA3WWBGFW4KFVnSW3f5iB-92I4RY9yYcg6Zwbgy1IExyXpIkvDkJx6YHXQ_e9Mof6r-n0m9I9HR7</recordid><startdate>200307</startdate><enddate>200307</enddate><creator>Movilli, Ezio</creator><creator>Cancarini, Giovanni C</creator><creator>Vizzardi, Valerio</creator><creator>Camerini, Corrado</creator><creator>Brunori, Giuliano</creator><creator>Cassamali, Silvia</creator><creator>Maiorca, Rosario</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200307</creationdate><title>Epoetin requirement does not depend on dialysis dose when Kt/N &gt; 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores</title><author>Movilli, Ezio ; Cancarini, Giovanni C ; Vizzardi, Valerio ; Camerini, Corrado ; Brunori, Giuliano ; Cassamali, Silvia ; Maiorca, Rosario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p547-f9ced04d0f607fd7025e7f98230919683d7a6923356bb49725b0d0a1a0f107da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biocompatible Materials</topic><topic>Cellulose</topic><topic>Cohort Studies</topic><topic>Dialysis Solutions - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Erythropoietin - administration &amp; dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Iron - blood</topic><topic>Iron - metabolism</topic><topic>Kidney Failure, Chronic - diagnosis</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Kidney Function Tests</topic><topic>Male</topic><topic>Membranes, Artificial</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Probability</topic><topic>Recombinant Proteins</topic><topic>Regression Analysis</topic><topic>Renal Dialysis - instrumentation</topic><topic>Renal Dialysis - methods</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Movilli, Ezio</creatorcontrib><creatorcontrib>Cancarini, Giovanni C</creatorcontrib><creatorcontrib>Vizzardi, Valerio</creatorcontrib><creatorcontrib>Camerini, Corrado</creatorcontrib><creatorcontrib>Brunori, Giuliano</creatorcontrib><creatorcontrib>Cassamali, Silvia</creatorcontrib><creatorcontrib>Maiorca, Rosario</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Movilli, Ezio</au><au>Cancarini, Giovanni C</au><au>Vizzardi, Valerio</au><au>Camerini, Corrado</au><au>Brunori, Giuliano</au><au>Cassamali, Silvia</au><au>Maiorca, Rosario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epoetin requirement does not depend on dialysis dose when Kt/N &gt; 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores</atitle><jtitle>Journal of nephrology</jtitle><addtitle>J Nephrol</addtitle><date>2003-07</date><risdate>2003</risdate><volume>16</volume><issue>4</issue><spage>546</spage><epage>551</epage><pages>546-551</pages><issn>1121-8428</issn><abstract>An inverse correlation between Kt/V and epoetin requirement has recently been demonstrated in stable hemodialysis (HD) patients with adequate iron stores, dialyzed with cellulosic membranes. However, there is no evidence as to whether or not this effect continues for Kt/V even in the adequate or higher range. We investigated the relationship between Kt/V and the weekly epoetin dose in 85 stable HD patients (age 63 +/- 16 years) treated with bicarbonate HD and unsubstituted cellulose membranes for 6-338 months (median: 70 months). HD for at least 6 months, subcutaneous rHuEPO for at least 4 months, transferrin saturation (TSAT) &gt; or = 20%, serum ferritin &gt; or = 100 ng/mL, hemoglobin (Hb) level targeted to approximately equal to 12 g/dL for at least 3 months. HBsAg and HIV positivity; need for blood transfusions or evidence of blood loss in the 3 months before the study, acute and chronic infections. To evaluate the effect of dialysis adequacy on the epoetin requirement, we also performed the same analysis after dividing of the patients according to Kt/V. Hematocrit (Hct) and Hb levels were evaluated weekly for 3 weeks; TSAT, serum ferritin, Kt/V, PCRn, serum albumin (sAlb), and weekly epoetin dose were evaluated at the end of observation. No change in dialysis or therapy prescription was made during the study. The results for all the patients were: Hct 36 +/- 2 %, Hb 12 +/- 0.7 g/dL, TSAT 28 +/- 7%, serum ferritin 234 +/- 171 ng/mL, sAlb 4.2 +/- 0.4 g/dL, Kt/V 1.33 +/- 0.17, PCRn 1.15 +/- 0.28 g/Kg/day, weekly epoetin dose 117 +/- 74 U/Kg. There was no correlation between Hb and Kt/V, whereas there was an inverse correlation between the reciprocal of the weekly epoetin dose and Kt/V (r = -0.448, p = 0.0001). Further regression line analysis showed a break-point for Kt/V at the level of 1.33. In the 52 patients with Kt/V &lt; 1.33, the correlation was confirmed between epoetin and Kt/V (r = - 0.563, p = 0.0001), while in the 33 patients with Kt/V &gt; or = 1.33, there was no correlation between epoetin dose and Kt/V (r = 0.021, p = NS). In these patients, multiple regression analysis, with the weekly epoetin dose as a dependent variable, confirmed Kt/V as a non-significant factor. In iron-replete HD patients on cellulosic membranes and stabilized epoetin therapy, inadequate dialysis was associated with higher epoetin requirement, but for Kt/V values &gt; or = 1.33, there was no further effect on epoetin responsiveness.</abstract><cop>Italy</cop><pmid>14696757</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1121-8428
ispartof Journal of nephrology, 2003-07, Vol.16 (4), p.546-551
issn 1121-8428
language eng
recordid cdi_proquest_miscellaneous_71496651
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Biocompatible Materials
Cellulose
Cohort Studies
Dialysis Solutions - pharmacology
Dose-Response Relationship, Drug
Drug Administration Schedule
Erythropoietin - administration & dosage
Female
Follow-Up Studies
Humans
Iron - blood
Iron - metabolism
Kidney Failure, Chronic - diagnosis
Kidney Failure, Chronic - therapy
Kidney Function Tests
Male
Membranes, Artificial
Middle Aged
Multivariate Analysis
Probability
Recombinant Proteins
Regression Analysis
Renal Dialysis - instrumentation
Renal Dialysis - methods
Risk Assessment
Severity of Illness Index
Treatment Outcome
title Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A13%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epoetin%20requirement%20does%20not%20depend%20on%20dialysis%20dose%20when%20Kt/N%20%3E%201.33%20in%20patients%20on%20regular%20dialysis%20treatment%20with%20cellulosic%20membranes%20and%20adequate%20iron%20stores&rft.jtitle=Journal%20of%20nephrology&rft.au=Movilli,%20Ezio&rft.date=2003-07&rft.volume=16&rft.issue=4&rft.spage=546&rft.epage=551&rft.pages=546-551&rft.issn=1121-8428&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71496651%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71496651&rft_id=info:pmid/14696757&rfr_iscdi=true